Phase 1/2 Study Of PF-06463922 (an Alk/ros1 Tyrosine Kinase Inhibitor) In Patients With Advanced Non-small Cell Lung Cancer Harboring Specific Molecular Alterations

Trial Profile

Phase 1/2 Study Of PF-06463922 (an Alk/ros1 Tyrosine Kinase Inhibitor) In Patients With Advanced Non-small Cell Lung Cancer Harboring Specific Molecular Alterations

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Lorlatinib (Primary) ; Crizotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 1 Apr 2018 to 1 Feb 2019.
    • 12 Sep 2017 Preliminary results (n=23) assessing efficacy and safety of lorlatinib in patients with ROS1-positive non-small cell lung cancer, presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results of phase II part of this study (n=65; as of 15 Aug 2016) presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top